Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) is experiencing a downtrend with a 9.1% decline over the past four weeks, but it is in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - TARS has an RSI reading of 28.74, indicating that the heavy selling pressure may be exhausting itself, suggesting a possible trend reversal [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for TARS by 10.2% over the last 30 days, indicating a strong consensus among sell-side analysts that could lead to price appreciation [6] - TARS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, further supporting the potential for a near-term turnaround [7]